StreetInsider.com News Articles

Form S-8 Alaunos Therapeutics,

Mon, 06 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732147.html

Form S-8 Alaunos Therapeutics,

Mon, 06 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732147.html

Form 4 Alaunos Therapeutics, For: Jun 30 Filed by: Weis Holger

Thu, 02 Jul 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26729694.html

Form 4 Alaunos Therapeutics, For: Jun 30 Filed by: Weis Holger

Thu, 02 Jul 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26729694.html

Alaunos shares preclinical liver data for metabolic drug ALN1003

Mon, 29 Jun 2026 08:35:26 -0400

Alaunos Therapeutics (Nasdaq: TCRT) released a new statistical analysis from a preclinical mouse study of its investigational oral small-molecule candidate ALN1003, showing lower liver weight in treated animals after adjustment for body fat percentage.

The analysis, drawn from a previously reported non-Good Laboratory Practice diet-induced obesity mouse study conducted over 48 days, found a statistically significant difference in liver weight between ALN1003-treated animals and controls after adjusting for body fat percentage, with a p-value of 0.000005 in a standard ANCOVA analysis. A sensitivity analysis using heteroscedasticity-robust HC3 standard errors produced a p-value of 0.000015.

According to the company, the finding indicates the

Alaunos shares preclinical liver data for metabolic drug ALN1003

Mon, 29 Jun 2026 08:35:26 -0400

According to the company, the finding indicates the

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Mon, 29 Jun 2026 08:35:00 -0400

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model
Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, an insulin-resistance-related biomarker, and favorable adipose endocrine signaling

FORT LAUDERDALE, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT), an early-stage biotechnology company developing novel therapeutics, today announced a new preclinical statistical analysis of liver weight adjusted for body fat

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Mon, 29 Jun 2026 08:35:00 -0400

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model
Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, an insulin-resistance-related biomarker, and favorable adipose endocrine signaling

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Mon, 29 Jun 2026 08:35:00 -0400

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model
Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, an insulin-resistance-related biomarker, and favorable adipose endocrine signaling

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Mon, 29 Jun 2026 08:35:00 -0400

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model
Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, an insulin-resistance-related biomarker, and favorable adipose endocrine signaling

Form 8-K Alaunos Therapeutics, For: Jun 29

Mon, 29 Jun 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26702633.html

Form 8-K Alaunos Therapeutics, For: Jun 29

Mon, 29 Jun 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26702633.html

Form 4 Alaunos Therapeutics, For: Jun 17 Filed by: Weis Holger

Wed, 17 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260617/26660689.html

Form 4 Alaunos Therapeutics, For: Jun 17 Filed by: Weis Holger

Wed, 17 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260617/26660689.html

Form 4 Alaunos Therapeutics, For: May 22 Filed by: Weis Holger

Wed, 27 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260527/26558474.html

Form 4 Alaunos Therapeutics, For: May 22 Filed by: Weis Holger

Wed, 27 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260527/26558474.html

Alaunos reports obesity drug shows weight loss in mouse studies

Tue, 26 May 2026 11:02:44 -0400

Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 demonstrated weight reduction and metabolic improvements in two mouse studies.

The Fort Lauderdale-based company said ALN1003 showed body weight reductions of up to 12.9% in a 48-day study and up to 30.5% in an 18-day dose-ranging study using diet-induced obese mice. The drug also reduced fat mass while maintaining lean muscle mass as a percentage of body weight.

In the longer study, mice treated with ALN1003 showed lower fasting insulin levels and improved insulin sensitivity markers. The treatment was associated with higher adiponectin levels and lower liver weight, along with

Alaunos reports obesity drug shows weight loss in mouse studies

Tue, 26 May 2026 11:02:44 -0400

Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 demonstrated weight reduction and metabolic improvements in two mouse studies.

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies